This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

The Effects of Omega-3 Fatty Acids on Metabolic Syndrome

The recruitment status of this study is unknown. The completion date has passed and the status has not been verified in more than two years.
Verified February 2012 by Pathmaja Paramsothy, University of Washington.
Recruitment status was:  Active, not recruiting
National Institutes of Health (NIH)
Northwest Lipid Research Clinic
Information provided by (Responsible Party):
Pathmaja Paramsothy, University of Washington Identifier:
First received: July 6, 2006
Last updated: February 29, 2012
Last verified: February 2012
The purpose of this study is to determine the effects of omega-3 fatty acids in the form of fish oil supplementation (approximately 2 grams per day) on the carotid intima-media (CIMT)progression (primary objective) and 2)(Secondary objective) lipid markers such as LDL, apo-B, and LDL buoyancy, on inflammatory burden as measured by CRP, on oxidative stress as measured by urinary isoprostanes, urine microalbumin/creatinine, and serum adiponectin a fat derived hormone in subjects with metabolic syndrome.

Condition Intervention Phase
Metabolic Syndrome X Dietary Supplement: Omega-3 fatty acids Early Phase 1

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double Blind (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Prevention
Official Title: Pilot Study: The Effects of Omega-3 Fatty Acids on Metabolic Syndrome and Vascular Structure in Metabolic Syndrome as Assessed by Carotid IMT

Resource links provided by NLM:

Further study details as provided by Pathmaja Paramsothy, University of Washington:

Primary Outcome Measures:
  • Change in Carotid IMT [ Time Frame: 1 year, 2 years ]

Secondary Outcome Measures:
  • Lipid (apolipoproteins and lipid parameters) [ Time Frame: 1 year, 2 years ]
  • hs-CRP & SAA [ Time Frame: 1 year, 2 years ]
  • Glucose [ Time Frame: 1 year, 2 years ]
  • Insulin [ Time Frame: 1 year, 2 years ]
  • adiponectin [ Time Frame: 1 year, 2 years ]
  • urine microalbumin/creatinine [ Time Frame: 1 year, 2 years ]
  • Serum Fatty Acids [ Time Frame: 1 year, 2 years ]

Estimated Enrollment: 100
Study Start Date: October 2006
Estimated Study Completion Date: June 2012
Primary Completion Date: October 2011 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Placebo Comparator: 1
Omega-3 fatty acid vs. placebo comparator
Dietary Supplement: Omega-3 fatty acids
Total of 1.8 grams of EPA +DHA in the form of fish oil capsules (3/day)
Other Name: Fish Oil

Detailed Description:
This translational pilot study will have a double-blind, placebo-controlled, parallel design. We will enroll one hundred subjects who meet at least 3 of the 5 criteria for metabolic syndrome as per NCEP guidelines/WHO guidelines and who do not have known cardiovascular disease or diabetes. They will receive either placebo or omega-3 fatty acids in the form of fish oil capsules for a two-year period. Assessment of, C-IMT, serum lipoprotein profile, LDL- buoyancy, adiponectin, CRP, SAA, apolipoprotein B and A-1, fasting glucose, fasting insulin levels, and plasma fatty acids will be measured at baseline, one year, and two years.

Ages Eligible for Study:   18 Years to 75 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • Adults with Metabolic Syndrome (meets 3 of the following 5)
  • Abdominal obesity, waist circumference in men greater than 40 in. & in women greater than 35 in.
  • Serum triglycerides greater than or = 150 mg/dL (1.7 mmol/L)
  • Serum HDL cholesterol less than or = 40 mg/dL in men and less than 50 mg/dL in women
  • Blood pressure greater than or = 130/85 mmHg or drug treatment for elevated blood pressure
  • Fasting plasma glucose greater than 100 mg/dL

Exclusion Criteria:

  • Diabetes
  • Known or documented CHD (including ECG consistent with prior MI), CVA (including TIA), PVD (including symptoms of claudication)
  • Angina or other chest pain that may indicate CHD
  • Clinically significant neoplastic, cardiovascular, hepatic, renal, metabolic, endocrine (untreated or unstable), or psychiatric (untreated or unstable)
  • Known abnormal LFTS greater than 2X ULN
  • Smoker, illicit drug use, or excessive alcohol use
  • Medications: Lipid lowering therapy, daily NSAID or greater than 325 mg ASA (PRN use ok), clopidogrel (or equivalent), Coumadin, Omega-3 fatty acid supplement, other investigational drugs within 30 days of study entry, high omega-3 fatty acid content in diet within past three months
  • Pregnancy or planning pregnancy during the study period
  • Sensitivity or allergy to fish
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00350194

United States, Washington
Northwest Lipid Research Clinic (University of Washington Affiliated)
Seattle, Washington, United States, 98104
Sponsors and Collaborators
University of Washington
National Institutes of Health (NIH)
Northwest Lipid Research Clinic
Principal Investigator: Pathmaja Paramsothy, MD University of Washington
  More Information

Responsible Party: Pathmaja Paramsothy, Assistant Professor of Medicine, University of Washington Identifier: NCT00350194     History of Changes
Other Study ID Numbers: 28791-D
05-8693-D 03
Study First Received: July 6, 2006
Last Updated: February 29, 2012

Keywords provided by Pathmaja Paramsothy, University of Washington:
Fatty Acids, Omega-3

Additional relevant MeSH terms:
Metabolic Syndrome X
Pathologic Processes
Insulin Resistance
Glucose Metabolism Disorders
Metabolic Diseases processed this record on August 16, 2017